Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients... Show more
Get AI intraday signals
A.I. Advisor
published Earnings
ROIV is expected to report earnings to fall 15.10% to -24 cents per share on August 18
Q2'25
Est.
$-0.25
Q1'25
Missed
by $0.03
Q4'24
Beat
by $0.48
Q3'24
Missed
by $0.02
Q2'24
Beat
by $0.36
The last earnings report on May 29 showed earnings per share of -28 cents, missing the estimate of -26 cents. With 11.13M shares outstanding, the current market capitalization sits at 7.74B.